Home›Stock Screener›Rekvina Laboratories

Rekvina Laboratories Share Price Today | Stock Price & Rekvina Laboratories Share Screener

VINRKLB Pharmaceuticals & Biotechnology
Live Share Price BSE
₹78.60
▲ 1.54 (2.00%)
2026-11-19 00:00:00

As of November 19, 2026, the live Rekvina Laboratories share price (BSE: VINRKLB) is ₹78.60, up 2.00% from the previous close, with shares trading between ₹78.60 and ₹78.60 in today's trading session, and a 52-week range of ₹7.08–₹78.60. Track Rekvina Laboratories market worth to gauge the company's total market size. Use the Rekvina Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Rekvina Laboratories opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Rekvina Laboratories Market Cap ₹80.70 Cr.
VINRKLB P/E Ratio (TTM) -234.30
Rekvina Laboratories P/B Ratio 20.92
EPS (TTM) ₹-0.42
Dividend Yield -
Debt to Equity -
VINRKLB 52 Week High ₹78.60
Rekvina Laboratories 52 Week Low ₹7.08
Operating Margin 8.00%
Profit Margin -
VINRKLB Revenue (TTM) ₹4.00
EBITDA -
Net Income -
Total Assets ₹1.00
Total Equity ₹-1.00

Rekvina Laboratories Share Price Chart

Track the current stock price of Rekvina Laboratories with an interactive chart. Analyse VINRKLB share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Rekvina Laboratories stock quote in one place.

The quote of ₹78.60 sits between the 52-week low of ₹7.08 and the 52-week high of ₹78.60, and the latest session moved 2.00% from the previous close.

Rekvina Laboratories Company Profile - Fundamental Screener

Screen Rekvina Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for VINRKLB shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE092O01028.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE092O01028

Rekvina Laboratories Balance Sheet Screener

Screen VINRKLB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹1.

Latest statistics put total assets at ₹1 and shareholder funds at ₹-1.

Item 2026 2025 2024 2023 2022 2021 2020 2018 2017 2016

Assets

Total Assets 1 0 0 0 0 0 0 1 1 1
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 0 0 0 0 0 0 0 0 0 0

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 0 0 0 0 0 0 0 0 0 0
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity -1 0 0 0 0 0 0 0 1 1
Share Capital 3 3 3 3 3 3 3 3 3 3
Reserves & Surplus -4 -3 -3 -3 -3 -3 -3 -3 -3 -3

Rekvina Laboratories Income Statement Screener - Profit & Revenue Analysis

Screen Rekvina Laboratories income statement and profit fundamentals. Analyze VINRKLB quarterly results. Rekvina Laboratories reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Sept, revenue was ₹4 and net profit was ₹0, equal to earnings per unit of ₹0.09, at an operating margin of 8%.

In that period expenses were ₹3, interest cost ₹0 and tax ₹0. The next period listed, 2026-Jun, shows revenue of ₹1 and net profit of ₹0.

Item 2026-Sept 2026-Jun 2025-Sept

Revenue and Expenses

Revenue 4 1 0
Expenses 3 1 0

Operating Costs and Margins

EBITDA 0 0 0
Operating Profit % 8.00% -18.00% -15.00%
Depreciation 0 0 0
Interest 0 0 0

Profit and Earnings

Profit Before Tax 0 0 0
Tax 0 0 0
Net Profit 0 0 0
EPS 0.09 -0.20 -0.06

Rekvina Laboratories Cash Flow Screener - Liquidity Fundamentals

Screen VINRKLB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities used ₹1.

Over the same period, investing activities provided ₹0 and financing activities provided ₹1.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2018-March 2017-March 2016-March 2015-March

Cash from Operations and Investing

Operating Activities -1 0 0 0 0 0 0 0 0 0
Investing Activities 0 0 0 0 0 0 0 0 0 0

Financing and Net Cash

Financing Activities 1 0 0 0 0 0 0 0 0 0
Net Cash Flow 0 0 0 0 0 0 0 0 0 0

Rekvina Laboratories Shareholding Pattern Screener

See Rekvina Laboratories shareholding pattern with promoter, FII, and DII holdings. Check Rekvina Laboratories promoter holding and ownership changes for VINRKLB on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 41.30%, foreign institutions 0.00%, domestic institutions 0.00% and the public 45.88%, spread across 2,475 shareholders.

The shareholder count was 2,475 in 2026-Mar, compared with 2,465 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Aug 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec

Promoter Holding

Promoter Holding 41.30% 41.30% 77.00% 77.00% 41.30% 41.30% 41.30% 41.30%

Institutional Investors

FII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
DII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 45.88% 45.86% 18.96% 20.03% 44.08% 45.96% 45.99% 45.99%
Other Holding 12.82% 12.85% 4.04% 2.97% 14.62% 12.74% 12.71% 12.71%
Shareholder Count 2,475 2,465 2,457 2,642 2,427 2,426 2,427 503

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Rekvina Laboratories. Rekvina Laboratories dividend yield can be compared with peers and other stocks in the market.

No dividends declared by Rekvina Laboratories.

Rekvina Laboratories Stock Index Membership - Nifty & Sensex

See which indices include Rekvina Laboratories stock. Check VINRKLB index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Rekvina Laboratories is not part of any tracked indices.
Only major market indices are tracked in our system.

Rekvina Laboratories Market Events Screener - Corporate Actions

Get Rekvina Laboratories corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Rekvina Laboratories stock events that may affect VINRKLB share price, along with derivatives, futures and options activity and sector gainers.

14 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 13, 2026, with a record date of November 13, 2026.

It is followed by Annual General Meeting dated September 29, 2026 and Quarterly Result Announcement dated August 13, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-13 2026-11-13 Quarterly Result Announcement NA 24.91%
2026-09-29 2026-09-29 Annual General Meeting NA -5.49%
2026-08-13 2026-08-13 Quarterly Result Announcement NA 35.28%
2026-05-21 2026-05-21 Quarterly Result Announcement NA -14.23%
2026-04-10 2026-04-10 Extraordinary General Meeting NA 31.26%
2026-02-06 2026-02-06 Quarterly Result Announcement NA 61.52%
2025-11-14 2025-11-14 Quarterly Result Announcement NA 0.00%
2025-09-26 2025-09-26 Annual General Meeting NA 0.00%
2025-08-13 2025-08-13 Quarterly Result Announcement NA 0.00%
2025-05-30 2025-05-30 Quarterly Result Announcement NA 0.00%
2025-01-20 2025-01-20 Quarterly Result Announcement NA 0.00%
2024-11-14 2024-11-14 Quarterly Result Announcement NA 0.00%
2024-09-27 2024-09-27 Annual General Meeting NA 0.00%
2024-08-12 2024-08-12 Annual General Meeting NA 0.00%

Rekvina Laboratories Competitors Screener - Peer Stocks Comparison

Screen VINRKLB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 451,075 41.10 61,674 12.69% 11,565 63.60
Divis Laboratories 303,749 90.70 11,067 13.95% 2,568 78.53
Torrent Pharmaceuticals 177,632 84.50 13,886 20.34% 2,138 47.27
Laurus Labs 130,972 98.10 6,868 22.01% 890 69.60
Zydus Life Science 118,693 27.60 27,658 17.64% 5,026 52.34
Dr Reddys Laboratories 115,186 41.70 35,059 3.90% 4,158 70.24
Cipla 112,438 39.40 29,045 2.24% 3,870 54.92
Mankind Pharma 109,044 48.40 14,636 14.85% 1,938 65.43
Aurobindo Pharma 104,903 26.40 34,145 5.56% 3,503 66.06
Lupin 90,557 17.30 29,039 26.75% 5,356 44.92

Rekvina Laboratories Company Announcements - News & Reports Screener

Screen VINRKLB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 18, 2026.

The next most recent announcements are dated November 18, 2026 and November 18, 2026.

Date Update Actions
2026-11-18 Compliance For Reg. 32 Statement Of Deviation & Variation -
2026-11-18 Appointment of Company Secretary and Compliance Officer -
2026-11-18 Financial Result For QTR2 -
2026-11-18 Board Meeting Outcome for Outcome Of Board Meeting -
2026-11-03 Board Meeting Intimation for Consider And Approve Financial Result For QTR2 -
2026-10-27 Intimation Regarding Temporary Shutdown Of Manufacturing Facility For Renovation Upgradation And Installation Of An Additional Vial Manufacturing Line. -
2026-10-15 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-10-07 Announcement under Regulation 30 (LODR)-Change in Management -
2026-09-29 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-29 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-24 Closure of Trading Window -
2026-09-23 Announcement Under Reg. 30 Of SEBI (LODR) Regulation 2015 - Noting Of Resignation -
2026-09-23 Announcement under Regulation 30 (LODR)-Change in Registered Office Address -
2026-09-12 Announcement under Regulation 30 (LODR)-Resignation of Chairman and Managing Director -
2026-09-03 Reg. 34 (1) Annual Report. -
2026-09-03 Shareholders Meeting To Be Held On 29.09.2026 Through Online Mode -
2026-09-02 Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer -
2026-08-18 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-08-17 Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 -
2026-08-14 Clarification On Price Movement -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹78.60, within a 52-week range of ₹7.08 to ₹78.60. The P/E ratio is -234.30 and the P/B ratio is 20.92, with earnings per unit of ₹-0.42. Market capitalisation stands at ₹80.70 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the BSE. Key statistics were last updated on November 20, 2026. This page covers 10 balance sheet periods, 3 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.